Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7878)	11/29/1998 8:30:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

You know I takes a big person to admit error. You did. IMO those views you posted are views and remain views until the facts are known. I find no fault in those in the "view" context. Now if we can go just one step further. How about bpi and its effect on the complement system and membrane attack complex. 1. Do you agree or disagree bpi has a "probable" effect upon it. 2. Do you agree or disagree that affecting the complement system at a specific point like C3a while leaving most of the other components intact would be beneficial. 3. If it did the above, would it be "potentially" a better anti-sepsis candidate than just a plain old anti-endotoxin?